Gastroesophageal reflux disease (GERD) is the most commonly diagnosed digestive disorder in the United States. Higher rates of non-erosive reflux disease (NERD) are found in females while higher rates of erosive reflux disease (ERD) are found in males. Pre-menopausal females appear to be protected from esophageal mucosal damage, as they demonstrate lower rates of ERD, Barrett’s esophagus, and esophageal adenocarcinoma. A protective effect of estrogen on the esophageal mucosa is thought to contribute to this decreased prevalence. A better understanding of sex-related differences in GERD may help alleviate the reported differences in outcomes between sexes regarding medical and surgical management.
KatzPOGersonLBVelaMF. Guidelines for the diagnosis and management of gastroesophageal reflux disease. Am J Gastroenterol. 2013;108(3):308-328; quiz 29.
2.
SandhuDSFassR. Current trends in the management of gastroesophageal reflux disease. Gut Liver. 2018;12(1):7-16.
3.
FassRFrazierR. The role of dexlansoprazole modified-release in the management of gastroesophageal reflux disease. Therap Adv Gastroenterol. 2017;10(2):243-251.
4.
El-SeragHBSweetSWinchesterCCDentJ. Update on the epidemiology of gastro-oesophageal reflux disease: a systematic review. Gut. 2014;63(6):871-880.
5.
FassROfmanJJ. Gastroesophageal reflux disease–should we adopt a new conceptual framework?Am J Gastroenterol. 2002;97(8):1901-1909.
6.
BadilloRFrancisD. Diagnosis and treatment of gastroesophageal reflux disease. World J Gastrointest Pharmacol Ther. 2014;5(3):105-112.
7.
LinMGersonLBLascarRDavilaMTriadafilopoulosG. Features of gastroesophageal reflux disease in women. Am J Gastroenterol. 2004;99(8):1442-1447.
8.
MinatsukiCYamamichiNShimamotoT, et al. Background factors of reflux esophagitis and non-erosive reflux disease: a cross-sectional study of 10,837 subjects in Japan. PLoS One. 2013;8(7):e69891.
9.
QuachDTHaQVNguyenCT, et al. Overlap of gastroesophageal reflux disease and functional dyspepsia and yield of esophagogastroduodenoscopy in patients clinically fulfilling the Rome IV criteria for functional dyspepsia. Front Med. 2022;9:910929.
10.
AsanumaKIijimaKShimosegawaT. Gender difference in gastro-esophageal reflux diseases. World J Gastroenterol. 2016;22(5):1800-1810.
11.
JaspersenDKuligMLabenzJ, et al. Prevalence of extra-oesophageal manifestations in gastro-oesophageal reflux disease: an analysis based on the ProGERD study. Aliment Pharmacol Ther. 2003;17(12):1515-1520.
12.
Mauvais-JarvisFBairey MerzNBarnesPJ, et al. Sex and gender: modifiers of health, disease, and medicine. Lancet. 2020;396(10250):565-582.
13.
KhanZAlastalYKhanMA, et al. On-Demand therapy with proton pump inhibitors for maintenance treatment of nonerosive reflux disease or mild erosive esophagitis: a systematic review and meta-analysis. Gastroenterol Res Pract. 2018;2018:6417526.
14.
WintersCJrSpurlingTJChobanianSJCurtisDJEspositoRLHackerJF3rd, et al. Barrett's esophagus. A prevalent, occult complication of gastroesophageal reflux disease. Gastroenterology. 1987;92(1):118-124.
15.
JohanssonKEAskPBoerydBFranssonSGTibblingL. Oesophagitis, signs of reflux, and gastric acid secretion in patients with symptoms of gastro-oesophageal reflux disease. Scand J Gastroenterol. 1986;21(7):837-847.
16.
BayerdörfferEBigardMAWeissW, et al. Randomized, multicenter study: on-demand versus continuous maintenance treatment with esomeprazole in patients with non-erosive gastroesophageal reflux disease. BMC Gastroenterol. 2016;16:48.
KimNLeeSWChoSI, et al. The prevalence of and risk factors for erosive oesophagitis and non-erosive reflux disease: a nationwide multicentre prospective study in Korea. Aliment Pharmacol Ther. 2008;27(2):173-185.
19.
CarlssonRDentJWattsR, et al. Gastro-oesophageal reflux disease in primary care: an international study of different treatment strategies with omeprazole. Eur J Gastroenterol Hepatol. 1998;10(2):119-124.
BirdMDKaravitisJKovacsEJ. Sex differences and estrogen modulation of the cellular immune response after injury. Cell Immunol. 2008;252(1-2):57-67.
22.
SekoKKagamiHSengaKOzekiKMizutaniHUedaM. Effects of ovariectomy and estrogen replacement on rat oral mucosa. Maturitas. 2005;50(1):44-51.
23.
VerdúEFDengYBercikPCollinsSM. Modulatory effects of estrogen in two murine models of experimental colitis. Am J Physiol Gastrointest Liver Physiol. 2002;283(1):G27-G36.
24.
GustafssonJA. An update on estrogen receptors. Semin Perinatol. 2000;24(1):66-69.
25.
KimYSKimNKimGH. Sex and gender differences in gastroesophageal reflux disease. J Neurogastroenterol Motil. 2016;22(4):575-588.
26.
IshiyamaFIijimaKAsanumaK, et al. Exogenous luminal nitric oxide exacerbates esophagus tissue damage in a reflux esophagitis model of rats. Scand J Gastroenterol. 2009;44(5):527-537.
27.
JacobsonBCMoyBColditzGAFuchsCS. Postmenopausal hormone use and symptoms of gastroesophageal reflux. Arch Intern Med. 2008;168(16):1798-1804.
28.
NilssonMJohnsenRYeWHveemKLagergrenJ. Obesity and estrogen as risk factors for gastroesophageal reflux symptoms. JAMA. 2003;290(1):66-72.
29.
NordenstedtHZhengZCameronAJYeWPedersenNLLagergrenJ. Postmenopausal hormone therapy as a risk factor for gastroesophageal reflux symptoms among female twins. Gastroenterology. 2008;134(4):921-928.
30.
UstaogluASawadaALeeC, et al. Heartburn sensation in nonerosive reflux disease: pattern of superficial sensory nerves expressing TRPV1 and epithelial cells expressing ASIC3 receptors. Am J Physiol Gastrointest Liver Physiol. 2021;320(5):G804-G15.
31.
KimJJKimNChoiYJKimJSJungHC. Increased TRPV1 and PAR2 mRNA expression levels are associated only with the esophageal reflux symptoms, but not with the extraesophageal reflux symptoms. Medicine. 2016;95(32):e4387.
32.
ShaheenNJFalkGWIyerPG, et al. Diagnosis and management of Barrett's Esophagus: an updated ACG guideline. Am J Gastroenterol. 2022;117(4):559-587.
33.
BryceCBucajMGazdaR. Barrett esophagus: rapid evidence review. Am Fam Physician. 2022;106(4):383-387.
34.
KambojAKKatzkaDAIyerPG. Endoscopic screening for Barrett’s esophagus and esophageal adenocarcinoma: rationale, candidates, and challenges. Gastrointest Endosc Clin N Am. 2021;31(1):27-41.
35.
VegaKJLangford-LeggTPalacioCWattsJJamalMM. Females without reflux symptoms or gastroesophageal reflux disease have less distal esophageal acid exposure than males without reflux symptoms or gastroesophageal reflux disease. Dis Esophagus. 2013;26(3):246-249.
36.
FassRSamplinerREMackelCMcGeeDRappaportW. Age- and gender-related differences in 24-hour esophageal pH monitoring of normal subjects. Dig Dis Sci. 1993;38(10):1926-1928.
37.
GyawaliCPFassR. Management of gastroesophageal reflux disease. Gastroenterology. 2018;154(2):302-318.
38.
SinghMLeeJGuptaN, et al. Weight loss can lead to resolution of gastroesophageal reflux disease symptoms: a prospective intervention trial. Obesity. 2013;21(2):284-290.
39.
SifrimDZerbibF. Diagnosis and management of patients with reflux symptoms refractory to proton pump inhibitors. Gut. 2012;61(9):1340-1354.
40.
El-SeragHBecherAJonesR. Systematic review: persistent reflux symptoms on proton pump inhibitor therapy in primary care and community studies. Aliment Pharmacol Ther. 2010;32(6):720-737.
41.
ZerbibFBredenoordAJFassR, et al. ESNM/ANMS consensus paper: diagnosis and management of refractory gastro-esophageal reflux disease. Neurogastroenterol Motil. 2021;33(4):e14075.
42.
LabenzJArmstrongDZetterstrandSEklundSLeodolterA. Clinical trial: factors associated with freedom from relapse of heartburn in patients with healed reflux oesophagitis–results from the maintenance phase of the EXPO study. Aliment Pharmacol Ther. 2009;29(11):1165-1171.
43.
RuigómezAJohanssonSWernerssonBFernández CanteroOGarcía RodríguezLA. Gastroesophageal reflux disease in primary care: using changes in proton pump inhibitor therapy as an indicator of partial response. Scand J Gastroenterol. 2012;47(7):751-761.
44.
LundellLHatlebakkJGalmicheJP, et al. Long-term effect on symptoms and quality of life of maintenance therapy with esomeprazole 20 mg daily: a post hoc analysis of the LOTUS trial. Curr Med Res Opin. 2015;31(1):65-73.
45.
FurutaTShimataniTSugimotoM, et al. Investigation of pretreatment prediction of proton pump inhibitor (PPI)-resistant patients with gastroesophageal reflux disease and the dose escalation challenge of PPIs—TORNADO study: a multicenter prospective study by the acid-related symptom research group in Japan. J Gastroenterol. 2011;46(11):1273-1283.
46.
HelgadóttirHMetzDCLundSH, et al. Study of gender differences in proton pump inhibitor dose requirements for GERD: a double-blind randomized trial. J Clin Gastroenterol. 2017;51(6):486-493.
47.
BentenWPStephanCLieberherrMWunderlichF. Estradiol signaling via sequestrable surface receptors. Endocrinology. 2001;142(4):1669-1677.
48.
MenonSNightingalePTrudgillN. Is hormone replacement therapy in post-menopausal women associated with a reduced risk of oesophageal cancer?United Eur Gastroenterol J. 2014;2(5):374-382.
49.
SalehSTrujilloSGhoneimSThomasCFassR. Effect of hormonal replacement therapy on gastroesophageal reflux disease and its complications in postmenopausal women. Clin Gastroenterol Hepatol. 2023;21(2):549-551. e3.
50.
MooreMAfanehCBenhuriDAntonacciCAbelsonJZarnegarR. Gastroesophageal reflux disease: a review of surgical decision making. World J Gastrointest Surg. 2016;8(1):77-83.
51.
ChenZThompsonSKJamiesonGGDevittPGWatsonDI. Effect of sex on symptoms associated with gastroesophageal reflux. Arch Surg. 2011;146(10):1164-1169.
52.
BeckPEWatsonDIDevittPGGamePAJamiesonGG. Impact of gender and age on the long-term outcome of laparoscopic fundoplication. World J Surg. 2009;33(12):2620-2626.
53.
OelschlagerBKQuirogaEParraJDCahillMPolissarNPellegriniCA. Long-term outcomes after laparoscopic antireflux surgery. Am J Gastroenterol. 2008;103(2):280-287; quiz 8.
54.
Maret-OudaJWahlinKEl-SeragHBLagergrenJ. Association between Laparoscopic Antireflux Surgery and recurrence of Gastroesophageal Reflux. JAMA. 2017;318(10):939-946.
55.
CamposGMPetersJHDeMeesterTR, et al. Multivariate analysis of factors predicting outcome after laparoscopic Nissen fundoplication. J Gastrointest Surg. 1999;3(3):292-300.
56.
GongEJParkCHJungDH, et al. Efficacy of endoscopic and surgical treatments for gastroesophageal reflux disease: a systematic review and network meta-analysis. J Pers Med. 2022;12:4.
57.
LiuJJDi SenaVOokuboRCarr-LockeDLSaltzmanJR. Endoscopic treatment of gastroesophageal reflux disease: effect of gender on clinical outcome. Scand J Gastroenterol. 2006;41(2):144-148.
